Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II Study of Safety and Efficacy of Lamivudine [EPIVIR] and Tenofovir Disoproxil Fumarate [VIREAD] Used to Lower the Plasma Level of Viral RNA of HERV-K(HML2) in Patients With Lymphoma

Next Previous
X
Search
Trial Profile

A Phase I/II Study of Safety and Efficacy of Lamivudine [EPIVIR] and Tenofovir Disoproxil Fumarate [VIREAD] Used to Lower the Plasma Level of Viral RNA of HERV-K(HML2) in Patients With Lymphoma

Status: Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 29 Oct 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lamivudine (Primary) ; Tenofovir disoproxil fumarate (Primary)
  • Indications Retrovirus infections
  • Focus Therapeutic Use

    • Most Recent Events

    • 10 Mar 2016 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov.
    • 31 Aug 2015 Planned End Date changed from 1 Aug 2016 to 1 Aug 2017 as reported by ClinicalTrials.gov record.
    • 31 Aug 2015 Planned initiation date changed from 1 Apr 2015 to 1 Dec 2015 as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top